JULY 2023LIFE SCIENCES REVIEW 19that are exclusive to cancer cells and viruses, Glycovax addresses the challenge of isolating and purifying these structures from biological sources. Glycovax distinguishes itself from other personalized medicine companies by targeting the glycan portion of proteins instead of concentrating only on the unique amino acid portion of specific proteins. The business model involves consolidating the necessary in-house expertise from R&D to clinical stages, expediting the development process by being proactive in the early stages. Glycovax further solves the issues early-stage drug developers face by managing all stages of drug development in-house through integrated operations while minimizing the use of CRO. Glycovax engages itself in the development of a commercial arm, focusing on the production of a crucial glycoconjugate vaccine component for its proprietary vaccines. Simultaneously, the company extends the offering to other vaccine developers from the same domain. This strategic approach serves multiple purposes, including generating financial resources to support ongoing R&D endeavours and fostering potential partnerships within the industry.Apart from its unique scientific approach in R&D, Glycovax has established a comprehensive company structure that integrates expertise across the multiple facets of drug development. Its inherent advantage is rooted in its status as a fully integrated company equipped with the necessary resources for comprehensive drug development in the field of glycoscience. It allows organizations to co-develop, where it can advance projects initiated by others who may lack expertise in more advanced stages, particularly in regulatory affairs and clinical development.Driven by a compelling mission to establish glycoscience as a catalyst for future therapeutic advancements, Glycovax draws inspiration from the transformative impact of mRNA vaccines in combating diseases like COVID-19 and addressing various infectious diseases and cancers. By harnessing the power of glycoscience, the company hopes to pave the way for significant breakthroughs in the field of therapeutics. Our differentiating factor lies in our scientific approach, which focuses on targeting glycans, setting us apart from other companies primarily focused on protein-based treatmentsDr. Serge Moffett, Scientific Director
< Page 9 | Page 11 >